Tag : L858R MUTATION

NEWS AND PERSPECTIVE

FDA approves the addition of chemotherapy to osimertinib in EGFRm advanced lung cancer
Osimertinib is a third-generation, orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) previously approved for the first-line treatment of EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).